Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Spexis AG
- Target Recruit Count
- 432
- Registration Number
- NCT03786094
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸Tallahassee Memorial HealthCare, Tallahassee, Florida, United States
🇺🇸West Virginia University Hospital, Morgantown, West Virginia, United States
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 557
- Registration Number
- NCT03734029
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Jilin Cancer Hospital, Chang chun, Jilin, China
Eribulin in Brain Metastases From HER2-negative Breast Cancer
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Institut Paoli-Calmettes
- Registration Number
- NCT03637868
- Locations
- 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
🇫🇷CHU Besançon, Besançon, France
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03583944
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇮🇳Lokmanya Hospital, Pune, Maharashtra, India
🇮🇳Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT03579472
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson General Hospital, Houston, Texas, United States
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03526679
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Monika Joshi, MD
- Target Recruit Count
- 6
- Registration Number
- NCT03502681
- Locations
- 🇺🇸
Univeristy of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Penn State Cancer Intsitute, Hershey, Pennsylvania, United States
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03441360
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
🇺🇸Children's Medical Center, Dallas, Texas, United States
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT03437083
- Locations
- 🇰🇷
Eisai Trial site_03, Ansan, Korea, Republic of
🇰🇷Eisai Trial site_02, Seoul, Korea, Republic of
🇰🇷Eisai Trial site_06, Busan, Korea, Republic of
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Amy Tiersten
- Target Recruit Count
- 9
- Registration Number
- NCT03430518
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.